Current Trends in Monoclonal Antibody Development and Manufacturing

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology, Specialties, Internal Medicine, Neuroscience, Science & Nature, Science
Cover of the book Current Trends in Monoclonal Antibody Development and Manufacturing by , Springer New York
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9780387766430
Publisher: Springer New York Publication: November 11, 2009
Imprint: Springer Language: English
Author:
ISBN: 9780387766430
Publisher: Springer New York
Publication: November 11, 2009
Imprint: Springer
Language: English

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade.

Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade.

Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.

More books from Springer New York

Cover of the book Phenology of Ecosystem Processes by
Cover of the book Mental Wellness Programs for Employees by
Cover of the book Surgical Anatomy and Technique by
Cover of the book Finnie's Notes on Fracture Mechanics by
Cover of the book The Lewin Legacy by
Cover of the book Common Problems in Acute Care Surgery by
Cover of the book Atlas of Conducted Electrical Weapon Wounds and Forensic Analysis by
Cover of the book Residue Reviews by
Cover of the book Biogeochemistry of a Forested Ecosystem by
Cover of the book An ASIC Low Power Primer by
Cover of the book Nonlinear Approaches in Engineering Applications 2 by
Cover of the book Dynamic Models of Infectious Diseases by
Cover of the book Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases by
Cover of the book Safety of Meat and Processed Meat by
Cover of the book Data Storage for Social Networks by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy